US · Healthcare · Medical Devices
EPS came in at -0.09 against a street estimate of -0.06 — a miss of 50.0%.
Analysts rate Cytek Biosciences Inc a hold (2 buy, 3 hold, 1 sell out of 6) with an average price target of $5.56.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.08% |
| Millennium Management LLC | 7.18% |
| Hillhouse Capital Advisors, Ltd. | 5.12% |
| Topline Capital Management LLC | 4.83% |
| Boston Partners Global Investors, Inc | 4.46% |
| Vanguard Capital Management, LLC | 3.66% |
| State Street Corp | 3.17% |
| Geode Capital Management, LLC | 2.18% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cytek Biosciences Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.